

Anita Kumar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3056832/publications.pdf>

Version: 2024-02-01

56
papers

1,473
citations

361413

20
h-index

345221

36
g-index

56
all docs

56
docs citations

56
times ranked

2665
citing authors

#	ARTICLE	IF	CITATIONS
1	CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. <i>Nature Medicine</i> , 2021, 27, 1280-1289.	30.7	365
2	Imaging for Staging and Response Assessment in Lymphoma. <i>Radiology</i> , 2015, 276, 323-338.	7.3	139
3	Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3109-3117.	1.6	97
4	Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. <i>Blood Cancer Journal</i> , 2020, 10, 74.	6.2	81
5	Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. <i>Blood Advances</i> , 2020, 4, 4669-4678.	5.2	64
6	Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. <i>Blood</i> , 2016, 128, 1458-1464.	1.4	61
7	Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2760-2769.	6.4	55
8	A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. <i>Blood</i> , 2018, 131, 1805-1808.	1.4	49
9	Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood</i> , 2019, 133, 2121-2129.	1.4	46
10	Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes. <i>Haematologica</i> , 2016, 101, 1237-1243.	3.5	42
11	Recurrent somatic JAK3 mutations in NK-cell enteropathy. <i>Blood</i> , 2019, 134, 986-991.	1.4	42
12	Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. <i>Blood</i> , 2021, 137, 39-48.	1.4	38
13	Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. <i>Blood Cancer Journal</i> , 2021, 11, 113.	6.2	35
14	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2257-2265.	1.6	32
15	Renal Masses Detected on FDG PET/CT in Patients With Lymphoma: Imaging Features Differentiating Primary Renal Cell Carcinomas From Renal Lymphomatous Involvement. <i>American Journal of Roentgenology</i> , 2017, 208, 849-853.	2.2	31
16	Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era. <i>British Journal of Haematology</i> , 2015, 171, 776-783.	2.5	30
17	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. <i>Blood Cancer Journal</i> , 2018, 8, 60.	6.2	25
18	[18F]FDG-PET/CT Radiomics for Prediction of Bone Marrow Involvement in Mantle Cell Lymphoma: A Retrospective Study in 97 Patients. <i>Cancers</i> , 2020, 12, 1138.	3.7	24

#	ARTICLE	IF	CITATIONS
19	Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. <i>Journal of Clinical Oncology</i> , 2023, 41, 541-554.	1.6	23
20	Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. <i>European Journal of Cancer</i> , 2020, 126, 78-90.	2.8	21
21	A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2991-2991.	1.4	21
22	Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. <i>Haematologica</i> , 2019, 104, e163-e166.	3.5	17
23	Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts. <i>American Journal of Hematology</i> , 2021, 96, 1211-1222.	4.1	16
24	Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. <i>Clinical Cancer Research</i> , 2022, 28, 45-56.	7.0	13
25	Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen). <i>Blood</i> , 2021, 138, 3540-3540.	1.4	12
26	Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 230-237.e12.	0.4	10
27	Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. <i>Blood Reviews</i> , 2015, 29, 143-152.	5.7	8
28	Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 613-626.	2.2	8
29	Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004259.	1.2	8
30	Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis. <i>Blood</i> , 2020, 136, 4-6.	1.4	7
31	Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma. <i>Haematologica</i> , 2022, 107, 1144-1152.	3.5	6
32	Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study. <i>Blood</i> , 2020, 136, 11-12.	1.4	6
33	Novel Agents in Mantle Cell Lymphoma. <i>Current Oncology Reports</i> , 2015, 17, 34.	4.0	5
34	Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 17-18.	1.4	5
35	Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1555-1555.	1.4	4
36	Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era. <i>Blood</i> , 2016, 128, 2955-2955.	1.4	4

#	ARTICLE	IF	CITATIONS
37	Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 46-47.	1.4	3
38	Incidence of Infectious Complications Associated with Bendamustine and Anti-CD20 Monoclonal Antibody Combination at Memorial Sloan Kettering Cancer Center (MSKCC). <i>Blood</i> , 2016, 128, 1778-1778.	1.4	3
39	Outcome of Initial Observation in Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 1803-1803.	1.4	3
40	Current Knowledge in Genetics, Molecular Diagnostic Tools, and Treatments for Mantle Cell Lymphomas. <i>Frontiers in Oncology</i> , 2021, 11, 739441.	2.8	3
41	Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 2177-2183.	1.3	2
42	CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population. <i>Blood</i> , 2020, 136, 50-51.	1.4	2
43	Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed. <i>Blood</i> , 2016, 128, 1777-1777.	1.4	2
44	Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience. <i>Blood</i> , 2019, 134, 2850-2850.	1.4	1
45	Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL). <i>Blood</i> , 2021, 138, 2447-2447.	1.4	1
46	Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era. <i>Blood</i> , 2020, 136, 36-38.	1.4	1
47	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, 29.	6.2	1
48	Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies. <i>Leukemia and Lymphoma</i> , 0, , 1-13.	1.3	1
49	Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications. <i>Leukemia and Lymphoma</i> , 2020, 61, 460-464.	1.3	0
50	Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay. <i>Blood</i> , 2015, 126, 2668-2668.	1.4	0
51	Outcomes of Follicular Lymphoma Patients By Dynamic FLIPI at Diagnosis and Initial Treatment in the Post-Rituximab Era. <i>Blood</i> , 2016, 128, 4119-4119.	1.4	0
52	Prognostic Significance of Genomic Alterations in Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 4115-4115.	1.4	0
53	Targeting CD30 in Patients with Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020, , 381-393.	0.2	0
54	Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2529-2529.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience. Blood, 2021, 138, 2513-2513.	1.4	0
56	Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience. Blood, 2021, 138, 4578-4578.	1.4	0